TLX
TELIX Pharmaceuticals Ltd
$13.39
▼ -1.40%
Market cap
$4.55B
Turnover
$17,475,773
Last price
$13.39
Day change
-1.40%
Announcements
10
Range, past year
Open 14.20 · Low 8.260 · Now 13.39 · High 29.64
Open TLX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
TLX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
31/100
Wyckoff phase
Accumulation4d
Trend stage
Neutral
1 Day
-1.4%
1 Week
-3.9%
1 Month
-14.9%
1 Year
-5.2%
RSI
42
Avg daily range
4.9%
TELIX Pharmaceuticals Ltd scores 31 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 4 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- MACD histogram positive & rising
Points to watch
- 60d drawdown -28.3%
- Risk rating: High
- Composite downside risk elevated
TLX announcements
Recent price-sensitive releases.
- 2026-10-21 Telix Reports Third Quarter 2026 Financial Performance Chair Appointment/Resignation | Periodic Reports - Other | Progress Report | Company Secretary Appointment/Resignation
- 2026-09-30 FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging Progress Report
- 2026-09-21 Telix and ITM Join Forces to Create Radiopharma Powerhouse Company Presentation | Progress Report
- 2026-09-14 FDA Approves Telix Brain Cancer Imaging Drug Pixclara Progress Report
- 2026-08-20 Telix HY26 Results Presentation Company Presentation | Half Yearly Report
- 2026-08-20 Telix HY26 Results Announcement Web Cast | Half Yearly Report
- 2026-08-20 Telix HY26 Appendix 4D and Interim Report Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
More Health Care stocks
Most traded in the same sector.